Liquid Biopsy for Brain Cancer

(ECLIPSE Trial)

This trial explores a new method for detecting brain cancer using a liquid biopsy. Instead of traditional tissue samples, researchers collect and analyze cerebrospinal fluid (CSF) and blood to identify cancer clues. The study includes patients with various stages of brain involvement, such as leptomeningeal disease or brain metastases, as well as those without brain involvement. Individuals with a solid tumor that has spread and who can undergo a spinal tap or have a device for fluid collection may be suitable candidates. The goal is to determine if these liquid biopsies (CSF and blood plasma) can effectively detect cancer markers. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could revolutionize cancer detection.

The trial information does not specify whether you need to stop taking your current medications. However, if you are on anticoagulant or antiplatelet medications, they must be safely interrupted for the lumbar puncture procedure.

Research has shown that taking samples of cerebrospinal fluid (CSF) and blood plasma is generally safe and well-tolerated by patients. Studies have found that CSF is particularly useful for detecting tumor DNA because it often contains more tumor-specific material than blood plasma. For instance, one study found mutations in the CSF of 95.2% of patients, compared to 66.7% in blood plasma. This suggests that using CSF for liquid biopsies might be a more sensitive method for monitoring brain cancer.

Researchers are excited about the liquid biopsy for brain cancer because it offers a non-invasive way to detect and monitor the disease. Unlike traditional biopsies, which require surgery to obtain tissue samples, this technique uses cerebrospinal fluid (CSF) and blood plasma, making it much less invasive and potentially safer for patients. This method could provide quicker and more frequent monitoring of tumor changes, allowing for more timely adjustments to treatment plans. Additionally, it holds promise for detecting brain cancer earlier than current imaging techniques, which could lead to better outcomes.

Research has shown that cerebrospinal fluid (CSF), the fluid around the brain and spine, is very useful for detecting materials from brain tumors, such as tumor DNA fragments. Studies have found that DNA from CSF provides a clearer picture of brain tumor changes than DNA from blood. One study found changes in the CSF DNA of 95.2% of patients, compared to 66.7% in blood DNA. This suggests that analyzing CSF might be more reliable for understanding brain tumors. In this trial, all participants will undergo a one-time collection of CSF and blood samples for liquid biopsy, a non-invasive method to monitor serious brain cancers like glioblastoma. Overall, these findings suggest that liquid biopsy is a promising tool for diagnosing and monitoring brain tumors.⁶⁷⁸⁹¹⁰